Document:

EX-10.28(xiii)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xiii) 

AMENDMENT NO. 11 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 11 (the “Eleventh Amendment”), effective as of July 09, 2013 (the “Eleventh Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer
Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered
into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment
No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7,
effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012 and Amendment No. 10, effective as of June 21, 2013 (hereinafter together the
“Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a “Party”, and collectively as the “Parties”. 

WHEREAS, FibroGen wishes BI Pharma (i) to [ * ] from [ * ] and (ii) to
[ * ] at BI Pharma, in both cases (i) and (ii) in compliance with the terms of the Supply Agreement as set forth in and as amended by this Eleventh Amendment. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Eleventh Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ], Version of July 09, 2013”, attached hereto as Exhibit A, is hereby added as an amendment to
Appendix 2 to the Supply Agreement. Pursuant thereto BI Pharma shall (i) [ * ] from [ * ] and (ii) [ * ] at BI Pharma, in both cases (i) and (ii) in accordance with the Supply
Agreement. 

  

	 	(3)	This Eleventh Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Eleventh Amendment, either oral or written, heretofore made with respect to subject matter
herein are expressly superseded by this Eleventh Amendment. 

  

	 	(4)	This Eleventh Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

  
 1 

					
	Amendment No. 11 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

IN WITNESS WHEREOF, the Parties have executed this Eleventh Amendment to the Supply Agreement as of Eleventh Amendment Effective Date. 

Biberach, July 23, 2013 
 BOEHRINGER
INGELHEIM PHARMA GMBH & CO. KG 
  

							
	ppa.	 		 	ppa.	  	
				
	 [ * ]
	 		 	 [ * ]
	  	
	[ * ]	 		 	[ * ]	  	
	VP Business & Contracts	 		 	Head of Team Biberach – Dep. Legal Germany

 San Francisco, July 31, 2013 

FIBROGEN, INC 
  

											
	 /s/ Jim Polarek
	 		 	  
	 	
	Name	 	 Jim Polarek
	 		 	Name	 	  
	 	
	Title	 	 Vice President
	 		 	Title	 	  
	 	

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 11 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 (Version of July 09, 2013) 

[ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(xiv)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xiv) 

AMENDMENT NO. 12 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 12 (the “Twelfth Amendment”), effective as of August 01, 2013 (the “Twelfth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer
Straße 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered
into by and between BI Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment
No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7,
effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 21, 2013 and Amendment No. 11,
effective as of June 26, 2013 (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a “Party”, and collectively as the “Parties”. 

WHEREAS, FibroGen wishes BI Pharma to [ * ] the terms of the Supply Agreement as set forth in and as amended by this
Twelfth Amendment. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Twelfth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ], Version of July 12 2013”, attached hereto as Exhibit A, is hereby added as an amendment to
Appendix 2 to the Supply Agreement. Pursuant thereto BI Pharma shall on behalf of FibroGen, [ * ] in accordance with the Supply Agreement. Parties are in agreement, that [ * ] such [ * ] under the
Supply Agreement and [ * ]. In the event that Parties agree to [ * ] in the further development of the Product, the terms and conditions of [ * ] in the course of the Project and
[ * ] are subject to separate discussion and agreement between the Parties. 

  

	 	(3)	This Twelfth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has not
been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Twelfth Amendment, either oral or written, heretofore made with respect to subject matter herein
are expressly superseded by this Twelfth Amendment. 

  

	 	(4)	This Twelfth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

  
 1 

					
	Amendment No. 12 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

IN WITNESS WHEREOF, the Parties have executed this Twelfth Amendment to the Supply Agreement as of Twelfth Amendment Effective Date. 

Biberach, July 18, 2013 
 BOEHRINGER
INGELHEIM PHARMA GMBH & CO. KG 
  

							
	ppa.	  		  	ppa.	  	
				
	 [ * ]
	  		  	 [ * ]
	  	
	[ * ]	  		  	[ * ]	  	
	VP Business & Contracts	  		  	Head of Team Biberach – Dep. Legal Germany	  	

 San Francisco, July 31, 2013 

FIBROGEN, INC 
  

											
	 /s/ Jim Polarek
	  		  	  
	  	
	Name	 	 Jim Polarek
	  		  	Name	  	  
	  	
	Title	 	 Vice President
	  		  	Title	  	  
	  	

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 12 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 (Version of July 12, 2013) 

-Page intentionally left blank- 

[ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.28(xv)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xv) 

AMENDMENT NO. 13 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 THIS AMENDMENT
NO. 13 (the “Thirteenth Amendment”), effective as of March 06, 2014 (the “Thirteenth Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173,
55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer
Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and
August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of
April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of
November 26, 2012, Amendment No. 10, effective as of June 21, 2013, Amendment No. 11, effective as of June 26, 2013 and Amendment No. 12, effective as of August 01, 2013 and subsequenty assigned by BI Pharma to BI
(hereinafter together the “Supply Agreement”). BI and FibroGen shall be referred to individually herein as a “Party”, and collectively as the “Parties”. 

WHEREAS, FibroGen wishes to engage BI to [ * ] in compliance with the terms of the Supply Agreement as set forth in and
as amended by this Thirteenth Amendment. The activities hereunder will be performed by BI Pharma on behalf of BI. 
 NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this ThirteenthAmendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	The Parties agree that pursuant to Section 2.2 of the Supply Agreement, the work plan entitled “[ * ], Version of March 6, 2014”, attached hereto as Exhibit A, is hereby added
as an amendment to Appendix 2 to the Supply Agreement. Pursuant thereto BI shall on behalf of FibroGen, (A) [ * ] after the [ * ] and provide the results to FibroGen and (B) manufacture in accordance with
the Supply Agreement (i) [ * ] as defined in the Amended and Restated Quality Agreement between the Parties dated March 03, 2011 (hereinafter “Amended and Restated Quality Agreement”),
(ii) [ * ] (as defined in the Amended and Restated Quality Agreement) [ * ], and (iii) [ * ] (as defined in the Supply Agreement). 

 

	 	(3)	The Specifications for [ * ] pursuant to Section 2 hereof have been agreed to by the Parties and are set forth in the Amended and Restated Quality Agreement by and between the Parties. Such
Specifications for [ * ], as applicable, shall apply to the activities contemplated by Section (2) above as part of the Acceptance Criteria for [ * ], respectively. 

  
 1 

					
	Amendment No. 13 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

 

	 	(4)	For the avoidance of doubt, all provisions of the Supply Agreement relating to the manufacture of Product which are reasonably applicable to [ * ] shall apply accordingly to [ * ] as
set forth in Exhibit A hereto, including but not limited the provisions regarding delivery of Product set forth in Section 4 of the Supply Agreement, Parties’ warranties set forth in Section 7 of the Supply Agreement (including, for
the avoidance of doubt, the disclaimer set forth in Section 7.5 of the Supply Agreement) and the limitations of BI Pharma’s liability and indemnification obligations set forth in Section 8 of the Supply Agreement. 

 

	 	(5)	This Thirteenth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has
not been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Thirteenth Amendment, either oral or written, heretofore made with respect to subject matter
herein are expressly superseded by this Thirteenth Amendment. 

  

	 	(6)	This Thirteenth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

 IN WITNESS WHEREOF, the
Parties have executed this Thirteenth Amendment to the Supply Agreement as of Thirteenth Amendment Effective Date. 
 Signatures on following page. 

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 13 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Ingelheim, March 7, 2014 
 BOEHRINGER
INGELHEIM BIOPHARMACEUTICALS GMBH 
  

							
	 ppa.
	 		  	 ppa.
  
	 	
				
	 [ * ]
	 		  	 [ * ]
	 	
	 [ * ]
	 		  	[ * ]	 	
	 VP Business & Contracts
	 		  	Head of Team Biberach – Dep. Legal Germany	 	

 San Francisco,
                     2014 

FIBROGEN, INC 
  

							
	 /s/ Michael Lowenstein
	 		  	 /s/ Jim Polarek
	 	
				
	 Name Michael Lowenstein
	 		  	 Name Jim Polarek
	 	
	 Title VP- Legal
	 		  	 Title VP
	 	

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 13 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 [ * ] 

(Version of March 06, 2014) 

[ * ] 

  

					
		 	4	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]